Progress in the cooperation with Synoptis Pharma

Since August 2023, ODI Pharma's exclusive cooperation with Synoptis Pharma (“Synoptis”), integral to the NEUCA group (“NEUCA”), has made notable progress. This alliance, spanning Poland and 23 other countries in Eastern Europe, has effectively executed several product shipments in recent months. These initial orders highlight the increasing demand and showcase ODI's operational ability, keeping the Company on the strategic path to achieve its short-term objectives by the end of Q1/2024. With the goal of operational profitability, this partnership with Synoptis is a critical step towards ODI’s aim of securing a substantial market share within the region.

The timing of this partnership aligns perfectly with the noticeable increase in demand for cannabis products in Poland, a trend further supported by the country's recent political elections. ODI views these developments as positive for the industry. The collaboration between ODI and Synoptis reflects a deep commitment to enhancing product accessibility. With Synoptis as part of the NEUCA group, a leading and innovative pharmaceutical entity in Eastern Europe, their joint efforts offer extensive expertise and market reach. Together, ODI and Synoptis are not just entering new markets but are making significant strides in ensuring that patients across Eastern Europe have access to medicinal cannabis.

ODI Pharma’s market share in Poland and Eastern Europe

In the dynamically changing European cannabis industry, nations such as Germany, Poland, Italy, Denmark, and Greece are leading the way in the adoption of medical cannabis. These countries are setting vital benchmarks for other emerging markets, including Switzerland, Luxembourg, France, and Spain. Amidst these developments, ODI Pharma is strategically enhancing its presence, with a focus on Poland and Eastern Europe. This region is witnessing increasing political support and major advancements in scientific research, both of which are contributing to the development of a stronger medical cannabis industry.

ODI Pharma's recent operational achievements and strategic partnerships demonstrate its dedication to being a significant player in the industry's evolution. By focusing on medical cannabis products and utilizing strong relationships with pharmacies and wholesalers, ODI is well-positioned to address the increasing demand for innovative and premium medical cannabis solutions. This strategic orientation aims to increase ODI's market share and extend its patient reach across these markets.

For more information on ODI Pharma, please contact:

Derek Simmross, CEO, ODI Pharma AB

E-mail: info@odipharma.com  

ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.